Abstract:The NMDA-R hypofunction model of schizophrenia started with the clinical observation of the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or ketamine. Healthy volunteers exposed to acute low doses of ketamine experienced mild psychosis but also negative and cognitive type symptoms reminiscent of the full clinical picture of schizophrenia. In rodents, acute systemic ketamine resulted in a paradoxical increase in extracellular frontal glutamate as well as of dopamine. Similar increase in prefrontal glutamate was documented with acute ketamine in healthy volunteers with 1H-MRS. Furthermore, sub-chronic low dose PCP lead to reductions in frontal dendritic tree density in rodents. In post-mortem ultrastructural studies in schizophrenia, a broad reduction in dendritic complexity and somal volume of pyramidal cells has been repeatedly described. This most likely accounts for the broad, subtle progressive cortical thinning described with MRI in- vivo. Additionally, prefrontal reductions in the obligatory GluN1 subunit of the NMDA-R has been repeatedly found in post-mortem tissue. The vast 1H-MRS literature in schizophrenia has documented trait-like small increases in glutamate concentrations in striatum very early in the illness, before antipsychotic treatment (the same structure where increased pre-synaptic release of dopamine has been reported with PET). The more recent genetic literature has reliably detected very small risk effects for common variants involving several glutamate-related genes. The pharmacological literature has followed two main tracks, directly informed by the NMDA-R hypo model: agonism at the glycine site (as mostly add-on studies targeting negative and cognitive symptoms); and pre-synaptic modulation of glutamatergic release (as single agents for acute psychosis). Unfortunately, both approaches have failed so far. There is little doubt that brain glutamatergic abnormalities are present in schizophrenia and that some of these are related to the etiology of the illness. The genetic literature directly supports a non- specific etiological role for glutamatergic dysfunction. Whether NMDA-R hypofunction as a specific mechanism accounts for any important component of the illness is still not evident. However, a glutamatergic model still has heuristic value to guide future research in schizophrenia. New tools to jointly examine brain glutamatergic, GABA-ergic and dopaminergic systems in-vivo, early in the illness, may lay the ground for a next generation of clinical trials that go beyond dopamine D2 blockade.

Functional connectivity signatures of NMDAR dysfunction in schizophrenia—integrating findings from imaging genetics and pharmaco-fMRI

Decreased Regional Homogeneity and Increased Functional Connectivity of Default Network Correlated with Neurocognitive Deficits in Subjects with Genetic High-Risk for Schizophrenia: A Resting-State Fmri Study.

Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function

A Framework for Linking Resting-State Chronnectome/genome Features in Schizophrenia: A Pilot Study

Associating Multimodal Neuroimaging Abnormalities with the Transcriptome and Neurotransmitter Signatures in Schizophrenia.

Dysconnectivity of the Medio-Dorsal Thalamic Nucleus in Drug-Naïve First Episode Schizophrenia: Diagnosis-Specific or Trans-Diagnostic Effect?

Neuroimaging biomarkers for drug discovery and development in Schizophrenia

Unveiling Functional Biomarkers in Schizophrenia: Insights from Region of Interest Analysis Using Machine Learning

Brain-Wide Functional Dysconnectivity in Schizophrenia: Parsing Diathesis, Resilience, and the Effects of Clinical Expression

Sustained NMDA Receptor Hypofunction Induces Compromised Neural Systems Integration and Schizophrenia-Like Alterations in Functional Brain Networks.

Thalamic connectivity measured with fMRI is associated with a polygenic index predicting thalamo-prefrontal gene co-expression

Ketamine Alters Functional Gamma and Theta Resting-State Connectivity in Healthy Humans: Implications for Schizophrenia Treatment Targeting the Glutamate System

Glutamatergic dysfunction in Schizophrenia

Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia

A Genetically Informed, Group Fmri Connectivity Modeling Approach: Application to Schizophrenia.

Disrupted Coupling Between NAA and Functional Connectivity in Ventromedial Prefrontal Cortex of Drug-Naïve First-Episode Psychosis.

Aberrant neuronal connectivity and network activity of neurons derived from patients with idiopathic schizophrenia

Exploring functional dysconnectivity in schizophrenia: alterations in eigenvector centrality mapping and insights into related genes from transcriptional profiles

Detecting Schizophrenia at the Level of the Individual: Relative Diagnostic Value of Whole-Brain Images, Connectome-Wide Functional Connectivity and Graph-Based Metrics

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Brain Function, Structure and Genomic Data Are Linked but Show Different Sensitivity to Duration of Illness and Disease Stage in Schizophrenia